COMMUNIQUÉS West-GlobeNewswire

Molecular Templates, Inc. Provides Interim Update
03/06/2024
Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients. Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in [...]
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
03/06/2024
SANTA ANA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]
InnovAge PACE Recertified as a Great Place to Work
03/06/2024
PACE Program Provides Highly Coordinated, Personalized Senior Care DENVER, June 03, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare [...]
Noom Launches Noom Vibe, a Wellness Community and Habit Tracker Built for the Age of GLP-1s
03/06/2024
Wellness App incentivizes healthy habits critical to whole-person health and longevity Answers Surgeon General Murthy’s call to integrate social connection into healthcare NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- [...]
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
03/06/2024
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare [...]
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
03/06/2024
New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled study [...]
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting
03/06/2024
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half ( hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a [...]
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
03/06/2024
START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseases DNL126 was selected as one of three CDER- [...]
BriaCell Presents Clinical Efficacy Data at ASCO 2024
03/06/2024
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature Bria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC [...]
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
03/06/2024
Evaxion’s AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patients Findings further confirm and validate the precision and predictive power of Evaxion [...]
EDAP Appoints New Executive Leaders to Strengthen Europe and Middle East Commercial Operations
03/06/2024
New appointments bring significant commercial experience with a focus on growing key strategic markets Expands executive leadership in growing disruptive, robotics-based capital equipment in both Urology and Gynecology [...]
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
03/06/2024
Ticker symbol change to take effect on Wednesday, June 5, 2024 SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in [...]
PetMed Express, Inc. Announces Strategic Updates to Executive Leadership Team
03/06/2024
Caroline Conegliano appointed Chief Operating Officer Umesh Sripad appointed Chief Digital and Technology Officer Company Announces CFO transition DELRAY BEACH, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- PetMed Express, [...]
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
03/06/2024
– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerability, and achieves [...]
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
03/06/2024
Sherry Korczynski joins the leadership team as Senior Vice President, Sales and Marketing Dr. Stephen Wargacki promoted to Chief Science Officer Cassie Jung named Chief Operating Officer WARREN, N.J., June 03, 2024 ( [...]
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
03/06/2024
MENLO PARK, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, [...]
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
03/06/2024
-- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response rate of 32.7% and duration of response consistent with the [...]
ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet Hematology
03/06/2024
The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) The combination showed substantial antileukemic activity with deep [...]
AVRICORE HEALTH CORPORATE UPDATE – COMPANY ACHIEVES PROFITABILITY
03/06/2024
VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the " Company " or “ Avricore ”) reports on results for the first three months of 2024, the first period of net [...]

Pages